



## PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Six Months Ended		Previous year ended
		30-Sep-2015	30-Jun-2015	30-Sep-2014	30-Sep-2015	30-Sep-2014	31-Mar-2015
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	<b>Income from operations</b>						
	(a) Net sales/income from operations (Net of excise duty)	11,676.14	10,098.14	13,983.12	21,774.28	28,136.28	52,085.50
	(b) Other operating income	-	-	-	-	-	-
	<b>Total income from operations (net) (a)+(b)</b>	11,676.14	10,098.14	13,983.12	21,774.28	28,136.28	52,085.50
2	<b>Expenses</b>						
	a) Cost of materials consumed	5,131.75	3,868.64	4,068.03	9,000.39	8,763.37	17,724.78
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,692.51)	(1,024.15)	2,078.07	(2,716.66)	2,030.19	347.95
	d) Employee benefits expense	1,107.57	954.22	781.19	2,061.79	1,692.56	3,651.16
	e) Depreciation and amortisation expense	449.80	290.46	321.38	740.26	714.80	1,177.58
	f) Other expenses - Manufacturing Expenses	1,921.74	1,562.45	1,552.84	3,484.19	2,992.46	6,444.21
	- R & D Expenses	1,506.29	1,593.60	1,347.49	3,099.89	2,493.80	5,596.26
	- Others	628.02	639.47	565.29	1,267.49	1,036.96	2,375.29
	<b>Total expenses</b>	9,052.66	7,884.69	10,714.29	16,937.35	19,724.14	37,317.23
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	2,623.48	2,213.45	3,268.83	4,836.93	8,412.14	14,768.27
4	Other Income	578.73	507.54	141.98	1,086.27	249.92	858.12
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	3,202.21	2,720.99	3,410.81	5,923.20	8,662.06	15,626.39
6	Finance costs	139.52	92.24	132.99	231.76	249.41	470.92
7	<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	3,062.69	2,628.75	3,277.82	5,691.44	8,412.65	15,155.47
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit/Loss from Ordinary Activities before tax (7+8)</b>	3,062.69	2,628.75	3,277.82	5,691.44	8,412.65	15,155.47
10	Tax Expenses	589.83	605.68	794.17	1,195.51	2,455.18	4,280.44
11	<b>Net Profit/ (Loss) from Ordinary Activities after tax (9-10)</b>	2,472.86	2,023.07	2,483.65	4,495.93	5,957.47	10,875.03
12	Extraordinary Items (net of tax expense Rs.____)	-	-	-	-	-	-
13	<b>Net Profit / (Loss) for the period (11 + 12)</b>	2,472.86	2,023.07	2,483.65	4,495.93	5,957.47	10,875.03
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)</b>	2,472.86	2,023.07	2,483.65	4,495.93	5,957.47	10,875.03
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,272.82	1,168.29	1,272.82	1,168.29	1,272.82
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	54,658.58
19.i	<b>Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):</b>						
	a) Basic	1.94	1.59	2.13	3.53	5.10	9.04
	b) Diluted	1.94	1.59	2.13	3.53	5.10	9.04
19.ii	<b>Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):</b>						
	a) Basic	1.94	1.59	2.13	3.53	5.10	9.04
	b) Diluted	1.94	1.59	2.13	3.53	5.10	9.04

PART - II							
A	PARTICULARS OF SHAREHOLDING	30-Sep-2015	30-Jun-2015	30-Sep-2014	30-Sep-2015	30-Sep-2014	31-Mar-2015
1	Public share holdings						
	a. Number of shares	51,462,478	51,624,902	41,171,212	51,462,478	41,171,212	51,624,902
	b. Percentage of share holding	40.43%	40.56%	35.24%	40.43%	35.24%	40.56%
2	<b>Promoters and promoter group Shareholding</b>						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,820,000	75,657,576	75,657,576	75,820,000	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	59.57%	59.44%	64.76%	59.57%	64.76%	59.44%
	Particulars	3 months ended (30/09/2015)					
B	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the quarter	-					
	Received during the quarter	116					
	Disposed of during the quarter	116					
	Remaining unresolved at the end of the quarter	-					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							
	PARTICULARS	Quarter ended			Six Months Ended		Previous year ended
		30-Sep-2015	30-Jun-2015	30-Sep-2014	30-Sep-2015	30-Sep-2014	31-Mar-2015
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	<b>SEGMENT REVENUE</b>						
	a) Manufacturing (CRAMS)	10,475.82	9,571.53	13,006.64	20,047.36	26,901.59	50,016.03
	b) Services (DDDSS)	1,200.32	526.61	976.48	1,726.92	1,234.69	2,069.47
	c) Research & Development	-	-	-	-	-	-
	<b>Net sales/income from operations</b>	<b>11,676.14</b>	<b>10,098.14</b>	<b>13,983.12</b>	<b>21,774.28</b>	<b>28,136.28</b>	<b>52,085.50</b>
2	<b>SEGMENT RESULTS (Profit/(Loss) before tax and interest)</b>						
	a) Manufacturing (CRAMS)	3,770.24	4,050.41	4,300.75	7,820.65	11,031.80	21,125.81
	b) Services (DDDSS)	813.15	234.17	737.95	1,047.32	772.84	1,113.29
	c) Research & Development	(1,506.27)	(1,593.61)	(1,347.49)	(3,099.88)	(2,588.84)	(5,596.26)
	<b>TOTAL</b>	<b>3,077.12</b>	<b>2,690.97</b>	<b>3,691.21</b>	<b>5,768.09</b>	<b>9,215.80</b>	<b>16,642.84</b>
	Less: (i) Interest	101.90	52.96	81.87	154.86	159.43	286.05
	(ii) Other Un-allocable expenses net off	(87.47)	9.26	331.52	(78.21)	643.72	1,201.32
	(iii) un-allocable Income	-	-	-	-	-	-
	<b>Profit Before Tax</b>	<b>3,062.69</b>	<b>2,628.75</b>	<b>3,277.82</b>	<b>5,691.44</b>	<b>8,412.65</b>	<b>15,155.47</b>
3	<b>CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)</b>						
	a) Manufacturing (CRAMS)	36,350.56	31,017.17	24,305.89	36,350.56	24,305.89	28,252.47
	b) Services (DDDSS)	3,460.06	3,836.40	3,211.14	3,460.06	3,211.14	3,612.25
	c) Research & Development	351.84	226.14	1,377.68	351.84	1,377.68	558.65
	d) Un-allocated	28,872.23	31,319.87	9,912.25	28,872.23	9,912.25	32,151.43
	<b>TOTAL</b>	<b>69,034.69</b>	<b>66,399.58</b>	<b>38,806.96</b>	<b>69,034.69</b>	<b>38,806.96</b>	<b>64,574.80</b>

**Notes:**

- 1) The above results were reviewed by the Audit Committee and approved by the Board of Directors' Meeting held on 10th November, 2015.
- 2) Corresponding previous period figures have been regrouped/ reclassified whenever necessary.
- 3) The Un-allocated assets as at 30th September, 2015 includes deposits with banks & investments in Liquid Mutual Funds of Rs. 24880.99 lakhs.
- 4) The above results were reviewed by Auditors.

For SUVEN LIFE SCIENCES LTD



Place : Hyderabad  
Date: 10th November, 2015

VENKAT JASTI  
Chairman & CEO  
DIN: 00278028

*We Deliver*



# SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

## Standalone Statement of Assets & Liabilities as per Clause 41 of the Listing Agreement

(Rs. In lakhs)

	Particulars	As at 30/09/2015	As at 31/03/2015
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholder's funds:</b>		
	(a) Share Capital	1,272.82	1,272.82
	(b) Reserves and Surplus	59,154.50	54,658.58
	<b>Sub-total - Shareholders' funds</b>	<b>60,427.32</b>	<b>55,931.40</b>
2	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	5,941.90	6,144.60
	(b) Deferred tax Liability (net)	2,438.00	2,271.33
	(c) Other long-term provisions	-	-
	(d) Long-term provisions	227.48	227.48
	<b>Sub-total - Non-current liabilities</b>	<b>8,607.38</b>	<b>8,643.41</b>
3	<b>Current liabilities</b>		
	(a) Short-term borrowings	3,429.72	2,823.51
	(b) Trade payables	4,524.56	4,389.08
	(c) Other current liabilities	3,763.88	4,244.59
	(d) Short-term provisions	495.75	1,281.42
	<b>Sub-total - Current liabilities</b>	<b>12,213.91</b>	<b>12,738.60</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>81,248.61</b>	<b>77,313.41</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Fixed assets	30,352.57	27,896.24
	(b) Non-current investments	-	-
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	964.50	1,088.74
	(e) Other non-current assets	581.41	630.54
	<b>Sub-total - Non-current assets</b>	<b>31,898.48</b>	<b>29,615.52</b>
2	<b>Current assets</b>		
	(a) Current investments	23,722.56	3.64
	(b) Inventories	10,396.89	8,180.55
	(c) Trade receivables	5,322.63	4,016.92
	(d) Cash and cash equivalents	1,283.63	27,968.90
	(e) Short-term loans and advances	8,598.32	7,459.80
	(f) Other current assets	26.10	68.08
	<b>Sub-total - Current assets</b>	<b>49,350.13</b>	<b>47,697.89</b>
	<b>TOTAL - ASSETS</b>	<b>81,248.61</b>	<b>77,313.41</b>

For Suvan Life Sciences Ltd

Venkat Jasti

Chairman & CEO

DIN: 00278028



Ref No.LR/005/2015-16:

**LIMITED REVIEW REPORT**

To


The Board of Directors of  
M/s. SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED ('the Company'), having registered office at 8-2-334, 6<sup>th</sup> Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the quarter ended on 30.09.2015 (the 'Statement'), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in accounting standard 25 "Interim Financial Reporting", specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,  
Chartered Accountants  
(Registration No.001757S)

  
(K. AJAY KUMAR)  
P A R T N E R  
M.No.021989



Place: Hyderabad  
Date : 10/11/2015



## News Release

### **Suven Revenue growth at 15.55%; PAT up by 22.23% for the Second quarter ended Sept, 2015**

**HYDERABAD, INDIA (10th November, 2015)** – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30<sup>th</sup> September 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 10th November, 2015 at Hyderabad.

#### **Financial Highlights for the 2nd Quarter ended September' 2015 (QoQ):**

Growth in revenue	INR 1226 Mn vs Rs 1061 Mn - up by 15.55%
Growth in PAT	INR 247 Mn vs. Rs 202 Mn - up by 22.23%
Growth in EBIDTA	INR 365 Mn vs. Rs 301Mn - up by 21.27%

#### **Financial Highlights for the Half year ended September' 2015:**

Growth in revenue	INR 2286 Mn vs Rs 2839 Mn - down by 19.47%
Growth in PAT	INR 450 Mn vs. Rs 596 Mn - down by 24.53%
Growth in EBIDTA	INR 666 Mn vs. Rs 938 Mn - down by 28.94%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 310 Mn (13.56% on revenue) for the half year ended Sept' 2015.

Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations during this quarter.

Based on the authorization during last Board meeting, Suven has incorporated a wholly owned subsidiary, **Suven, Inc.**, a Delaware Company in USA and the same become operational from October 2015.

For more information on Suven please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*

## **Suven Life Sciences Limited**

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor

Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | Telangana | India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)



# SUVEN Life Sciences Ltd

## **Communication to investors** **September 2015**

10-Nov-15

*2015-16 Q2 results*



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



# FINANCIAL QUICK VIEW

	FY 2015-16 Q2 to Q1	FY 2015-16 HY Sep 15
Growth in revenue	15.55%	-19.47%
Growth in PAT	22.23%	-24.53%
Growth in EBIDTA	21.27%	-28.94%
Growth in Pre-R&D EBIDTA	12.01%	-17.75%
Increase in R&D Costs	-5.48%	24.30%
R&D to sales	12.29%	13.56%







# MAJOR PROFITABILITY RATIOS



	Q2 Sep 15	HY Sep 15
PAT to Income	20.18%	19.67%
EBIDTA to Income	29.80%	29.15%
Cash Flow to Income	23.85%	22.90%
Pre-R&D EBITDA to Income	42.09%	42.71%




# Q2 to Q1 COMPARISON





# REVENUE COMPARISON




10-Nov-15

2015-16 Q2 results




# PAT COMPARISON



10-Nov-15

2015-16 Q2 results

# EBIDTA COMPARISON




10-Nov-15

2015-16 Q2 results




# R & D – EXPENDITURE





# PRE-R&D EBIDTA




10-Nov-15

2015-16 Q2 results



# PRE-R&D CASHFLOW







# FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2015-16 Q2	2015-16 Q1	Growth %	2014-15 Q2	Growth %	2015-16 1HY	2014-15 1HY	Growth %
<b>Income</b>	<b>1,225.49</b>	<b>1,060.57</b>	<b>15.55%</b>	<b>1,412.51</b>	<b>-13.24%</b>	<b>2,286.06</b>	<b>2,838.62</b>	<b>-19.47%</b>
Pre-R&D EBITDA	515.83	460.51	<b>12.01%</b>	507.97	<b>1.55%</b>	976.34	1,187.07	<b>-17.75%</b>
<b>Pre-R&amp;D EBITDA Margin</b>	<b>42.09%</b>	<b>43.42%</b>		<b>35.96%</b>		<b>42.71%</b>	<b>41.82%</b>	
EBITDA	365.20	301.15	<b>21.27%</b>	373.22	<b>-2.15%</b>	666.35	937.69	<b>-28.94%</b>
<b>EBITDA Margin</b>	<b>29.80%</b>	<b>28.39%</b>		<b>26.42%</b>		<b>29.15%</b>	<b>33.03%</b>	
EBIT	320.22	272.10	<b>17.69%</b>	341.08	<b>-6.12%</b>	592.32	866.21	<b>-31.62%</b>
<b>EBIT Margin</b>	<b>26.13%</b>	<b>25.66%</b>		<b>24.15%</b>		<b>25.91%</b>	<b>30.52%</b>	
Financing costs	13.95	9.22		13.30		23.18	24.94	
<b>Taxes</b>	<b>58.98</b>	<b>60.57</b>		<b>79.42</b>		<b>119.55</b>	<b>245.52</b>	
Net Profit after tax	247.29	202.31	<b>22.23%</b>	248.37	<b>-0.43%</b>	449.59	595.75	<b>-24.53%</b>
<b>NP Margin</b>	<b>20.18%</b>	<b>19.08%</b>		<b>17.58%</b>		<b>19.67%</b>	<b>20.99%</b>	
EPS (basic & diluted not annualised)	1.94	1.59		2.13		3.53	5.10	
<b>Paid up share capital (One Rupee Share)</b>	<b>127.28</b>	<b>127.28</b>		<b>116.83</b>		<b>127.28</b>	<b>116.83</b>	
Depreciation	44.98	29.05		32.14		74.03	71.48	
<b>R&amp;D expenses</b>	<b>150.63</b>	<b>159.36</b>	<b>-5.48%</b>	<b>134.75</b>	<b>11.78%</b>	<b>309.99</b>	<b>249.38</b>	<b>24.30%</b>

# News Release



- Suven secures five Product Patents in China, Israel, Mexico, Singapore and Sri Lanka
- Suven secures three Product Patents in Canada and China
- Suven bags Pharmexcil's "Gold Patent Award"
- Suven secures three Product Patents in New Zealand, Singapore and USA
- Suven secures five Product Patents for their NCE's in Australia, China, Europe, South Korea and USA
- Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations during this quarter



# News Release

- SUVN-D4010 for Cognition in Alzheimer's disease commenced Phase 1 Clinical Trial in USA under US-IND126099 in September 2015
- Suven participated at Society for Neuroscience (SFN-2015) Chicago, USA held during October 17-21 and presented data on several of their NCE's
- Suven presented at Bio-Europe 2015 Partnering conference held during November 2-4, 2015 in Munich, Germany
- Suven presented at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during November 5-7, 2015 at Barcelona, Spain
- Based on the authorization during last Board meeting, Suven has created a wholly owned subsidiary, **Suven, Inc.**, a Delaware Company in USA and the same become operational from October 2015